FibroBiologics, Inc. Common Stock (FBLG)
USD 2.01
(-6.51%)
USD 2.01
(-6.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 437 Thousand | 94 Thousand | - | - |
| Gross Profit | -437 Thousand | -94 Thousand | - | - |
| Operating Expenses | 8.88 Million | 4.37 Million | 1.57 Million | 1.16 Million |
| Selling, General and Administrative Expenses | 6.52 Million | 3.22 Million | 1.05 Million | 500 Thousand |
| Research and Development Expenses | 2.36 Million | 1.14 Million | 521 Thousand | 669 Thousand |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 8.88 Million | 4.46 Million | 1.57 Million | 1.16 Million |
| Operating Income | -8.88 Million | -4.46 Million | -1.57 Million | -1.16 Million |
| Interest Expense | 147 Thousand | 654 Thousand | 4000.00 | - |
| Income Tax Expense | - | - | - | - |
| Earnings before Tax | -16.48 Million | -5.12 Million | -1.58 Million | -1.16 Million |
| Net Income | -16.48 Million | -5.12 Million | -1.58 Million | -1.16 Million |
| Earnings Per Share Basic | -0.59 | -0.16 | -0.05 | -0.13 |
| Earnings Per Share Diluted | -0.68 | -0.16 | -0.05 | -0.13 |
| Weighted Average Shares Outstanding | 32.49 Million | 32.49 Million | 32.49 Million | 8.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 28.23 Million | 32.49 Million | 32.49 Million | 8.75 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -15.9 Million | -4.37 Million | -1.57 Million | - |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 140 Thousand | 137 Thousand | 130 Thousand | 437 Thousand | 112 Thousand | - |
| Gross Profit | -140 Thousand | -137 Thousand | -130 Thousand | -437 Thousand | -112 Thousand | - |
| Operating Expenses | 3.08 Million | 3.31 Million | 2.35 Million | 8.45 Million | 1.93 Million | 2.09 Million |
| Selling, General and Administrative Expenses | 2.14 Million | 2.38 Million | 1.6 Million | - | 1.37 Million | 1.55 Million |
| Research and Development Expenses | 938 Thousand | 925 Thousand | 742 Thousand | - | 561 Thousand | 543 Thousand |
| Other Expenses | 30 Thousand | -5.04 Million | -7.23 Million | -7.44 Million | -141 Thousand | -57 Thousand |
| Cost and Expenses | 3.22 Million | 3.45 Million | 2.48 Million | 8.88 Million | 2.05 Million | 2.09 Million |
| Operating Income | -3.22 Million | -3.45 Million | -2.48 Million | -8.88 Million | -2.05 Million | -2.09 Million |
| Interest Expense | 5000.00 | 4000.00 | 1000.00 | 147 Thousand | - | 11 Thousand |
| Income Tax Expense | - | - | - | - | 1.00 | -46 Thousand |
| Earnings before Tax | 898 Thousand | -8.46 Million | -9.71 Million | -16.48 Million | -2.19 Million | -2.16 Million |
| Net Income | 898 Thousand | -8.46 Million | -9.71 Million | -16.48 Million | -2.19 Million | -2.16 Million |
| Earnings Per Share Basic | 0.03 | -0.26 | -0.34 | - | -0.07 | -0.07 |
| Earnings Per Share Diluted | 0.03 | -0.26 | -0.34 | - | -0.07 | -0.07 |
| Weighted Average Shares Outstanding | 32.71 Million | 32.71 Million | 28.23 Million | 28.23 Million | 32.49 Million | 32.47 Million |
| Weighted Average Shares Outstanding (Diluted) | 32.71 Million | 32.71 Million | 28.23 Million | 28.23 Million | 32.49 Million | 32.47 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -3.08 Million | -3.31 Million | -2.35 Million | - | -1.93 Million | -2.05 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
605388
1088
BNAI
BOWFF
600161
STMRF